Synthego bags $41M to grow CRISPR synthetic RNA kit biz

Sythengo has persuaded some big names to back its expansion

Synthetic RNA kit business Synthego has raised $41 million to step up its efforts to make CRISPR gene editing easier and more accurate. The West Coast startup relied heavily on tech VCs for the cash, but also gained validation from having CRISPR pioneer Jennifer Doudna invest in its business.

Redwood City, CA-based Synthego exited stealth in August, four years after it was set up by two former SpaceX computer engineers. In those early years, which were bankrolled by an $8.3 million investment in 2013, Synthego established an automated manufacturing process for guide RNA products that it thinks sets it apart from larger competitors in terms of cost, turnaround time and editing efficiency.

Sythengo has persuaded some big names it is on to something. 8VC, an infrastructure-focused VC that also invested in uBiome, led the round with support from fellow new backers AME Cloud Ventures, Elements Capital, OS Fund, Alexandria Equities and ZhenFund. Existing investors including Peter Thiel’s Founders Fund and Menlo Ventures also contributed to the Series B round.

Whitepaper Download

Reducing the Complexity and Costs of Channel Planning and Logistics

How can you make the process of bringing your product to market less complex while also reducing costs? This Whitepaper identifies opportunities to simplify channel strategies for biopharma companies, their customers and patients. Discover how you can deliver savings and innovation to your business.

Most notably from a tech-validation perspective, Synthego also secured investment from Jennifer Doudna, a University of California, Berkeley professor who played a starring role in the contested emergence of CRISPR/Cas9 gene editing. Doudna rates Synthego's platform.

"Synthego's platform uniquely enables scientists to conduct genome engineering research in a highly efficient, affordable, and scalable way," Doudna said in a statement. "The RNA synthesis capabilities of Synthego's team represent a significant leap forward for synthetic biology."

Having secured the funding, Synthego plans to build out its commercial operation, expand globally and step up its work on new products.

The current centerpiece of Synthego’s pitch to researchers is a full length 100-mer synthetic sgRNA product it claims it can ship within a week at a cost five times lower than competitors.


Suggested Articles

Seven developers will provide digital health solutions aimed at the COVID-19 pandemic, including smartphone apps, wearables and big data programs.

Illumina will drop $8 billion to reacquire its former spinout, which after nearly five years is nearing completion of its cancer-seeking blood test.

Bausch Health is paying $10 million upfront for the option to acquire Allegro Ophthalmics’ eye disease assets, with a promise of $40 million to come.